SIETES :: 92758 citas

Resultados de la búsqueda por ANSIEDAD REFINAR BÚSQUEDA

1.

Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry 2019:21 de mayo. [Ref.ID 103125]

2.

Slee A, Nazareth I, Bondaronek P, Liu Y, Chenq Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019;393:23 de febrero. [Ref.ID 103110]

3.

Torjesen I. Pregabalin and gabapentin: what impact will reclassification have on doctors and patients?. BMJ 2019;364:11 de marzo. [Ref.ID 103081]

4.

Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]

5.

Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]

6.

Watson S, Härmark L. Desogestrel and panic attacks – a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports. Br J Clin Pharmacol 2018;84:agosto. [Ref.ID 102860]

7.

Begley S. ‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims — and finding some truth. STAT 2018:23 de agosto. [Ref.ID 102810]

8.

Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry 2018:16 de agosto. [Ref.ID 102798]

9.

Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ 2017;358:j3927. [Ref.ID 102068]

10.

Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]

11.

Anónimo. Psilocybin may reduce depression and anxiety in some cancer patients, studies suggest. DIA Daily 2016:1. [Ref.ID 100992]

12.

Anónimo. Pfizer loses UK appeal over pregabalin patent dispute. DIA Daily 2016:1. [Ref.ID 100808]

13.

Rubin R. Senators urge expedited evaluation of medical use of cannabidiol. JAMA 2016;316:13 de julio. [Ref.ID 100491]

14.

Bradford AC, Bradford D. Medical marijuana laws reduce prescription medication use In Medicare Part D. Health Affairs 2016;37:julio. [Ref.ID 100483]

15.

Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176:238246. [Ref.ID 100117]

16.

Ee C, Xue C, Chondros P, Myers SP, French SD, Teede H, Pirotta M. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med 2016;164:146-54. [Ref.ID 100116]

17.

Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase. Drug Saf 2016;39:69-78. [Ref.ID 100084]

18.

Dubicka B, Cole-King A, Reynolds S, Ramchandani P. Paper on suicidality and aggression during antidepressant treatment was flawed and the press release was misleading. BMJ 2016;352:i911. [Ref.ID 100053]

19.

Sharma T, Guski LS, Freund N, Gotzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016;352:i65. [Ref.ID 100036]

20.

Moncrieff J. Misrepresenting harms in antidepressant trials. BMJ 2016;352:i217. [Ref.ID 100033]